Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Br J Nutr ; 130(8): 1444-1457, 2023 10 28.
Artículo en Inglés | MEDLINE | ID: mdl-36805853

RESUMEN

The European Food Safety Authority has suggested that EU countries implement the 2 × 24 h diet recall (2 × 24 h DR) method and physical activity (PA) measurements for national dietary surveys. Since 2000, Denmark has used 7 d food diaries (7 d FD) with PA questionnaires and measurements. The accuracy of the reported energy intakes (EI) from the two diet methods, pedometer-determined step counts and self-reported time spent in moderate-to-vigorous PA (MVPA) were compared with total energy expenditure measured by the doubly labelled water (TEEDLW) technique and with PA energy expenditure (PAEE), respectively. The study involved fifty-two male and sixty-eight female volunteers aged 18-60 years who were randomly assigned to start with either the 24 h DR or the web-based 7 d FD, and wore a pedometer for the first 7 d and filled in a step diary. The mean TEEDLW (11·5 MJ/d) was greater than the mean reported EI for the 7 d FD (9·5 MJ/d (P < 0·01)) but the same as the 2 × 24 h DR (11·5 MJ/d). The proportion of under-reporters was 34 % (7 d FD) and 4 % (2 × 24 h DR). Most participants preferred the 7 d DR as it was more flexible, despite altering their eating habits. Pearson's correlation between steps corrected for cycling and PAEE was r = 0·44, P < 0·01. Spearman's correlation for self-reported hours spent in MVPA and PAEE was r = 0·58, P < 0·01. The 2 × 24 h DR performs better than the existing 7 d FD method. Pedometer-determined steps and self-reported MVPA are good predictors of PAEE in adult Danes.


Asunto(s)
Dieta , Agua , Adulto , Femenino , Humanos , Masculino , Dinamarca , Registros de Dieta , Ingestión de Energía , Metabolismo Energético , Internet , Adolescente , Adulto Joven , Persona de Mediana Edad
2.
Psychiatry Res ; 212(2): 125-31, 2013 May 30.
Artículo en Inglés | MEDLINE | ID: mdl-23137806

RESUMEN

Numerous studies indicate that the serotonergic (5-HT) transmitter system is involved in the regulation of impulsive aggression and there is from post-mortem, in vivo imaging and genetic studies evidence that the 5-HT2A receptor may be involved. We investigated 94 healthy individuals (60 men, mean age 47.0±18.7, range 23-86) to determine if trait aggression and trait impulsivity were related to frontal cortex 5-HT2A receptor binding (5-HT2AR) as measured with [18F]-altanserin PET imaging. Trait aggression and trait impulsivity were assessed with the Buss-Perry Aggression Questionnaire (AQ) and the Barratt Impulsiveness Scale 11 (BIS-11). Statistical analyses were conducted using a multiple linear regression model and internal consistency reliability of the AQ and BIS-11 was evaluated by Cronbach's alpha. Contrary to our hypothesis, results revealed no significant associations between 5-HT2AR and the AQ or BIS-11 total scores. Also, there was no significant interaction between gender and frontal cortex 5-HT2AR in predicting trait aggression and trait impulsivity. This is the first study to examine how 5-HT2AR relates to trait aggression and trait impulsivity in a large sample of healthy individuals. Our findings are not supportive of a selective role for 5-HT2AR in mediating the 5-HT related effects on aggression and impulsivity in psychiatrically healthy individuals.


Asunto(s)
Agresión/fisiología , Lóbulo Frontal/metabolismo , Conducta Impulsiva/metabolismo , Receptor de Serotonina 5-HT2A/metabolismo , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Femenino , Fluorodesoxiglucosa F18 , Lóbulo Frontal/diagnóstico por imagen , Hormonas/metabolismo , Humanos , Conducta Impulsiva/diagnóstico por imagen , Ketanserina/análogos & derivados , Ketanserina/farmacocinética , Masculino , Persona de Mediana Edad , Personalidad , Inventario de Personalidad , Tomografía de Emisión de Positrones , Antagonistas de la Serotonina/farmacocinética , Estadísticas no Paramétricas , Adulto Joven
3.
Int J Neuropsychopharmacol ; 15(8): 1099-107, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21846421

RESUMEN

Genetic variation in 5-HT transporter (5-HTT) expression is a key risk factor for psychiatric disorder and has been linked to changes in the expression of certain 5-HT receptor subtypes. This study investigated the effect of variation in 5-HTT expression on 5-HT4 receptor levels in both 5-HTT knockout (KO) and overexpressing (OE) mice using autoradiography with the selective 5-HT4 receptor radioligand, [³H]SB207145. Compared to wild-type (5-HTT⁺/⁺) controls, homozygous 5-HTT KO mice (5-HTT⁻/⁻) had reduced 5-HT4 receptor binding site density in all brain regions examined (35-65% of 5-HTT⁺/⁺). In contrast, the density of 5-HT4 receptor binding sites was not significantly different between heterozygous 5-HTT KO mice (5-HTT⁻/⁺) and 5-HTT⁺/⁺ mice. The 5-HT synthesis inhibitor p-chlorophenylalanine (250 mg/kg twice daily for 3 d) abolished the difference in 5-HT4 binding between 5-HTT⁻/⁻ and 5-HTT⁺/⁺ mice in all brain regions. Compared to wild-type (WT) littermate controls, 5-HTT OE mice had increased 5-HT4 binding density across all brain regions, except amygdala (118-164% of WT) and this difference between genotypes was reduced by the 5-HTT inhibitor, fluoxetine (20 mg/kg twice daily, 3 d). Together, these findings suggest that variation in 5-HTT expression causes adaptive changes in 5-HT4 receptor levels which are directly linked to alterations in 5-HT availability.


Asunto(s)
Encéfalo/metabolismo , Regulación de la Expresión Génica/genética , Variación Genética/genética , Receptores de Serotonina 5-HT4/metabolismo , Proteínas de Transporte de Serotonina en la Membrana Plasmática/genética , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo , Análisis de Varianza , Animales , Autorradiografía , Encéfalo/diagnóstico por imagen , Encéfalo/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Fluoxetina/farmacología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Piperidinas/farmacocinética , Piperidinas/farmacología , Propano/análogos & derivados , Propano/farmacología , Unión Proteica/efectos de los fármacos , Unión Proteica/genética , Cintigrafía , Receptores de Serotonina 5-HT4/genética , Serotoninérgicos/farmacología , Proteínas de Transporte de Serotonina en la Membrana Plasmática/deficiencia , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Tritio/farmacocinética
4.
Neurosci Lett ; 476(2): 58-61, 2010 May 31.
Artículo en Inglés | MEDLINE | ID: mdl-20381585

RESUMEN

The 5-HT(4) receptor modulates activity of serotonergic neurons and is a new potential target for antidepressant treatment. This microdialysis study evaluated the effect of the 5-HT(4) receptor agonist, RS67333, on extracellular serotonin (5-hydroxytryptamine, 5-HT) and 5-HIAA levels in rat ventral hippocampus during chloral hydrate anaesthesia, and explored the ability of RS67333 to augment the effect of the selective serotonin reuptake inhibitor paroxetine. The effect of RS67333 was examined after acute and subchronic (3 days) administration. Acute RS67333 (1.5mg/kg i.v.) had no effect on extracellular 5-HT or 5-HIAA levels, while acute paroxetine (0.5mg/kg i.v.) increased 5-HT levels by 299+/-16% and decreased 5-HIAA levels by 25+/-4%. Administration of RS67333 80 min after paroxetine caused an additional transient increase in 5-HT levels (to 398+/-52% of baseline). Subchronic RS67333 administration (1.5mg/kg i.p.) increased basal 5-HT levels by 73+/-15% and decreased 5-HIAA levels by 27+/-13%. In conclusion, the 5-HT(4) receptor agonist RS67333 augmented the acute effect of paroxetine on extracellular 5-HT levels in the ventral hippocampus, and after 3 days increased basal hippocampal 5-HT levels.


Asunto(s)
Compuestos de Anilina/farmacología , Hipocampo/efectos de los fármacos , Paroxetina/farmacología , Piperidinas/farmacología , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Agonistas del Receptor de Serotonina 5-HT4 , Serotonina/metabolismo , Animales , Sinergismo Farmacológico , Espacio Extracelular/metabolismo , Hipocampo/metabolismo , Ácido Hidroxiindolacético/metabolismo , Masculino , Microdiálisis , Ratas , Ratas Sprague-Dawley
5.
Neurosci Lett ; 392(1-2): 129-34, 2006 Jan 09.
Artículo en Inglés | MEDLINE | ID: mdl-16213658

RESUMEN

Depletion of rat brain serotonin (5-hydroxytryptamin, 5-HT) has been widely used to study effects of serotonin and its interaction with other transmitter systems. Various treatment regimes for serotonin depletion have been applied, but the efficacy of these seems to vary considerably. So far, no studies have systematically examined and compared different approaches. The present work combines quantitative and qualitative measurements and compares six different treatment schemes for 5-HT depletion. Treatment outcome was evaluated by HPLC measurements of 5-HT and 5-HIAA concentrations, and by 5-HT and tyrosine hydroxylase immunocytochemistry. The schemes included repeated administration of fenfluramine (FEN) and/or p-chlorophenylalanine (pCPA). The most efficient treatment for rat brain 5-HT depletion was the combined treatment with one daily pCPA (200 mg/kg) injection for 3 days followed by one injection of d,l-FEN (20 mg/kg) on the fourth day, causing a 94.9% brain 5-HT depletion. Immunostaining revealed a distinct brain distribution of the remaining 5-HT, with an almost complete depletion of 5-HT in the cerebral cortex, hippocampus and thalamus, while a substantial amount of 5-HT still was left in the raphe nuclei, the medial forebrain bundle, and the medial eminence. FEN or pCPA treatment alone caused from 68.2 to 94.0% decrease in 5-HT levels. While the pattern of 5-HT depletion using pCPA alone was comparable to the one seen with the combined treatment, the 5-HT depletion using FEN alone showed a different pattern with 5-HT distributed in several brain regions.


Asunto(s)
Química Encefálica/fisiología , Encéfalo/metabolismo , Serotonina/deficiencia , Animales , Encéfalo/efectos de los fármacos , Encéfalo/patología , Química Encefálica/efectos de los fármacos , Cromatografía Líquida de Alta Presión/métodos , Esquema de Medicación , Interacciones Farmacológicas , Fenfluramina/farmacología , Ácido Hidroxiindolacético/metabolismo , Masculino , Ratas , Ratas Sprague-Dawley , Serotonina/fisiología , Serotoninérgicos/farmacología , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , p-Cloroanfetamina/farmacología
6.
Am J Hum Genet ; 73(6): 1217-39, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14639525

RESUMEN

The devastating genetic disorder Cockayne syndrome (CS) arises from mutations in the CSA and CSB genes. CS is characterized by progressive multisystem degeneration and is classified as a segmental premature-aging syndrome. The CS complementation group B (CSB) protein is at the interface of transcription and DNA repair and is involved in transcription-coupled and global genome-DNA repair, as well as in general transcription. Recent structure-function studies indicate a process-dependent variation in the molecular mechanism employed by CSB and provide a starting ground for a description of the mechanisms and their interplay.


Asunto(s)
Síndrome de Cockayne/genética , ADN Helicasas/genética , Reparación del ADN/genética , Transcripción Genética/genética , Mapeo Cromosómico , Síndrome de Cockayne/fisiopatología , ADN Helicasas/fisiología , Reparación del ADN/fisiología , Enzimas Reparadoras del ADN , Humanos , Modelos Genéticos , Proteínas de Unión a Poli-ADP-Ribosa , Transcripción Genética/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...